John G. Ullman & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

John G. Ullman & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.88M	Sell	32,693 -140	-0.4%	-$30.7K	0.96%	32
2026 Q1	$6.21M	Sell	32,833 -1,567	-5%	-$274K	0.82%	38
2025 Q4	$5.85M	Sell	34,400 -975	-3%	-$149K	0.78%	39
2025 Q3	$4.66M	Sell	35,375 -535	-1%	-$64.2K	0.63%	51
2025 Q2	$3.81M	Sell	35,910 -3,208	-8%	-$348K	0.57%	58
2025 Q1	$4.86M	Sell	39,118 -632	-2%	-$82.4K	0.75%	44
2024 Q4	$4.9M	Sell	39,750 -5,344	-12%	-$630K	0.72%	47
2024 Q3	$5.02M	Sell	45,094 -11,400	-20%	-$1.25M	0.72%	48
2024 Q2	$6.03M	Buy	56,494 +26,344	+87%	+$2.9M	0.92%	33
2024 Q1	$3.63M	Buy	+30,150	New	+$3.69M	0.56%	56

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

John G. Ullman & Associates's JAZZ Position: Q2 2026 in Review

John G. Ullman & Associates reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.43% in Q2 2026, selling an estimated $30.7K and leaving 32,693 shares worth $7.88M. The position accounts for 0.96% of the portfolio, ranked #32.

John G. Ullman & Associates first reported a position in JAZZ in Q1 2024 and has held it in 10 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

John G. Ullman & Associates held 32,693 shares of Jazz Pharmaceuticals worth $7.88M as of Q2 2026.
John G. Ullman & Associates sold 140 Jazz Pharmaceuticals shares in Q2 2026, an estimated $30.7K.
Jazz Pharmaceuticals made up 0.96% of John G. Ullman & Associates's portfolio in Q2 2026, its #32 holding.
John G. Ullman & Associates first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on John G. Ullman & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.